No Data
No Data
With 89% Institutional Ownership, Biogen Inc. (NASDAQ:BIIB) Is a Favorite Amongst the Big Guns
How Is The Market Feeling About Biogen?
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
Investors Can Find Comfort In Biogen's (NASDAQ:BIIB) Earnings Quality
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $251
No Data
webguybob : The Etsy downgrade surprised me!
105535782 : ok
102242135 Lim : K